Literature DB >> 8931872

Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA.

P Neuner1, M Pourmojib, G Klosner, F Trautinger, R Knobler.   

Abstract

The soluble tumour necrosis factor receptor I (sTNFRI, p55) is produced at similar levels by both immortalized (A431, HaCaT, KB) and primary normal human keratinocytes (HNK), whereas the soluble TNFR II (sTNFR II, p75) appears to be specifically released only by immortalized human keratinocytes. The purpose of this study was to investigate whether the increase in p75 secretion by immortalized human keratinocytes is due to an increased shedding of the receptor from the cell membrane, or is related to increased steady-state levels of p75 mRNA. FACS analysis showed that levels of membranous p75 decreased in a time-dependent manner in immortalized cells cultured for 1, 3, 6, 12 and 24 h, while remaining unchanged in HNK throughout. Northern blot analysis showed that after 12 h of culture, when p75 expression was decreased on the cell membrane of all immortalized cells, there was no significant difference in steady state levels of p75 mRNA between immortalized keratinocytes and HNK. Supernatants of immortalized cells, cultured for 24 h contained distinct levels of p75, while levels of p75 in supernatants of HNK were under the detection limit, confirming that the p75 decrease on the cell membrane results from increased p75 shedding from the cell membrane of immortalized cells. In contrast to p75, p55 was continuously expressed on the cell membrane of normal and immortalized keratinocytes without significant variation throughout the entire 24-h culture period and was similarly shed by both cell types. These results suggest that immortalized keratinocytes are specifically activated for shedding of p75 from the cell membrane. Since p75 has a high affinity for TNF, the release of this receptor may imply a direct role in the escape of malignant/transformed keratinocytes from the TNF-mediated immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931872     DOI: 10.1007/bf02505279

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  25 in total

1.  Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis.

Authors:  B Heilig; M Wermann; H Gallati; M Brockhaus; B Berke; O Egen; A Pezzutto; W Hunstein
Journal:  Clin Investig       Date:  1992-01

2.  55-kd tumor necrosis factor receptor is expressed by human keratinocytes and plays a pivotal role in regulation of human keratinocyte ICAM-1 expression.

Authors:  U Trefzer; M Brockhaus; H Loetscher; F Parlow; A Kapp; E Schöpf; J Krutmann
Journal:  J Invest Dermatol       Date:  1991-11       Impact factor: 8.551

3.  A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.

Authors:  T Kohno; M T Brewer; S L Baker; P E Schwartz; M W King; K K Hale; C H Squires; R C Thompson; J L Vannice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

4.  The 55-kD tumor necrosis factor receptor on human keratinocytes is regulated by tumor necrosis factor-alpha and by ultraviolet B radiation.

Authors:  U Trefzer; M Brockhaus; H Lötscher; F Parlow; A Budnik; M Grewe; H Christoph; A Kapp; E Schöpf; T A Luger
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

5.  Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy.

Authors:  E A Grosen; G A Granger; M Gatanaga; E K Ininns; C Hwang; P DiSaia; M Berman; A Manetta; D Emma; T Gatanaga
Journal:  Gynecol Oncol       Date:  1993-07       Impact factor: 5.482

6.  Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus.

Authors:  D Aderka; A Wysenbeek; H Engelmann; A P Cope; F Brennan; Y Molad; V Hornik; Y Levo; R N Maini; M Feldmann
Journal:  Arthritis Rheum       Date:  1993-08

7.  Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

Authors:  D Aderka; H Englemann; V Hornik; Y Skornick; Y Levo; D Wallach; G Kushtai
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

8.  Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy.

Authors:  A Belldegrun; W Pierce; D Sayah; J deKernion; D Wallach; D Aderka; R A Figlin
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-04

9.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

Authors:  K J Van Zee; T Kohno; E Fischer; C S Rock; L L Moldawer; S F Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

10.  High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia.

Authors:  W Digel; F Porzsolt; M Schmid; F Herrmann; W Lesslauer; M Brockhaus
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

View more
  1 in total

1.  Transactivation of the EGF receptor in A431 human carcinoma cells upon exposure to heat shock.

Authors:  A L Evdonin; N V Tsupkina; N N Nikol'skii; N D Medvedeva
Journal:  Dokl Biol Sci       Date:  2005 Mar-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.